Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioRestorative Therapies Inc BRTX

Healthcare Biotechnology
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured... see more

Recent & Breaking News (NDAQ:BRTX)

BioRestorative Therapies to Evaluate Cell Delivery Technology to Advance Metabolic Program Towards Human Trials

GlobeNewswire July 20, 2015

BioRestorative Therapies to Evaluate Cell Delivery Technology to Advance Metabolic Program Towards Human Trials

GlobeNewswire July 20, 2015

BioRestorative Therapies, Inc. Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ Capital Market

GlobeNewswire July 6, 2015

BioRestorative Therapies Announces Conversion of $5.15 Million of Debt to Equity

GlobeNewswire June 2, 2015

BioRestorative Therapies to Present ThermoStem(R) Data at 21st Annual Meeting of the International Society for Cellular Therapy

GlobeNewswire May 27, 2015

BioRestorative Therapies to Present at the 2015 Marcum MicroCap Conference in New York City

GlobeNewswire May 26, 2015

BioRestorative Therapies, Inc. Announces Opening of New Headquarters and Laboratory Facility in New York

Business Wire April 14, 2015

BioRestorative Therapies Appoints Charles S. Ryan, J.D., Ph.D. to its Board of Directors

Business Wire April 8, 2015

BioRestorative Therapies Announces the Appointment of Edward Field as President of the brtxDISC(TM) Division

Business Wire February 17, 2015

BioRestorative Therapies, Inc. to Present at Inaugural Innovations Conference

Business Wire February 5, 2015

BioRestorative Therapies Appoints Dr. Joy Cavagnaro to Scientific Advisory Board

Business Wire February 2, 2015

BioRestorative Therapies Reports Successful Meeting with FDA

Business Wire January 12, 2015

BioRestorative Therapies Schedules Pre-IND Meeting with FDA

Business Wire November 24, 2014

BioRestorative Therapies Announces Relocation To New York State

Business Wire September 3, 2014

BioRestorative Therapies Engages Consulting Firm to Develop Strategic Partnerships in Japan and China

Business Wire August 18, 2014

BioRestorative Therapies Issues Letter to Stockholders

Business Wire July 14, 2014

BioRestorative Therapies Appoints Joseph B. Swiader to its Board of Directors

Business Wire July 2, 2014

BioRestorative Therapies Appoints The Honorable Paul Jude Tonna to its Board of Directors

Business Wire June 30, 2014

BioRestorative Therapies to Present at the Third Annual Marcum MicroCap Conference

Business Wire May 28, 2014

BioRestorative Therapies Signs Research Agreement with Pfizer Inc.

Business Wire May 22, 2014